Drug
Mgd007 Mga012
Mgd007 Mga012: highest development phase Phase 1/2, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGD007 + MGA012 NCT03531632 | Phase 1/2 | Colorectal Cancer Metastatic |
Latest
No recent events.
Follow Mgd007 Mga012 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.